CriticalFirst-generation antipsychotic, diphenylbutylpiperidine derivative×Calcineurin inhibitor (immunosuppressant)
Updated · Methodology
Mechanism
Pimozide prolongs the QT interval on the electrocardiogram, so an additive effect on QT can be expected with other QT-prolonging drugs. The US pimozide label names tacrolimus among them (pimozide label, US Food and Drug Administration, FDA). Tacrolimus itself may prolong the QT interval and may cause torsade de pointes (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and tacrolimus FDA label). CYP3A4 and CYP2D6 are the main enzymes that metabolise pimozide, and higher pimozide levels may increase the risk of QT prolongation (pimozide SmPC, AEMPS). The Spanish tacrolimus SmPC describes tacrolimus as a known CYP3A4 inhibitor that may affect the metabolism of drugs handled by CYP3A4 (tacrolimus SmPC, AEMPS). The documents do not say how much tacrolimus changes pimozide levels.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. With pimozide, very rare cases of QT prolongation, ventricular arrhythmias and torsade de pointes have been reported, even in people without risk factors. Ventricular tachycardia and ventricular fibrillation, sometimes fatal, have also been reported (pimozide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With tacrolimus, ventricular arrhythmias and cardiac arrest are uncommon, and torsade de pointes and QT prolongation on the ECG are very rare (tacrolimus SmPC, AEMPS). Tacrolimus commonly lowers blood magnesium, potassium and calcium, and its Spanish SmPC lists electrolyte disturbances among the risk factors for QT prolongation (tacrolimus SmPC, AEMPS).
Management
The combination is contraindicated. The US pimozide label contraindicates pimozide with QT-prolonging drugs and states that pimozide should not be given with tacrolimus (pimozide label, US Food and Drug Administration, FDA). The Spanish pimozide summary of product characteristics (SmPC) contraindicates pimozide with drugs known to prolong the QT interval and with drugs that inhibit the enzyme CYP3A4 (pimozide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to its own SmPC, tacrolimus prolongs QT and inhibits CYP3A4 (tacrolimus SmPC, AEMPS). In the tacrolimus documents, the Spanish SmPC advises caution with QT-prolonging drugs. When tacrolimus is combined with CYP3A4 substrates or inhibitors that also prolong QT, the US label recommends a lower tacrolimus dose, frequent monitoring of tacrolimus blood levels and QT monitoring (tacrolimus SmPC, AEMPS, and FDA label). No document states how long to wait after stopping pimozide before starting tacrolimus. The mean elimination half-life of pimozide in people with schizophrenia is about 55 hours (pimozide SmPC, AEMPS). Pimozide is contraindicated in QT prolongation, known low potassium or magnesium and clinically significant bradycardia. Record an electrocardiogram (ECG) before starting pimozide and periodically during treatment, and stop pimozide if the QT or corrected QT interval (QTc) exceeds 500 ms (pimozide SmPC, AEMPS). In the early post-transplant period, check the ECG and electrolytes, especially potassium, routinely (tacrolimus SmPC, AEMPS). For people with risk factors for QT prolongation, including other QT-prolonging drugs, the US label advises considering ECGs and periodic monitoring of magnesium, potassium and calcium (tacrolimus FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Pimozide tablets, USP (ANI Pharmaceuticals) – prescribing information (2026)– FDA label, ANI Pharmaceuticals, DailyMed setid 4e954fc2-fdff-486c-beb6-2b8ace717081, version 3, 07/2026, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica de Prograf 0,5 mg cápsulas duras (tacrolimus) (2026)– AEMPS, CIMA, nº registro 63189, secciones 4.4 y 4.5
- FDA: Prograf (tacrolimus) prescribing information (2025)– Astellas Pharma US. PROGRAF (tacrolimus) capsules, injection, granules. Prescribing information, DailyMed setid 7f667de1-9dfa-4bd6-8ba0-15ee2d78873b, sections 4, 5.11 and 7
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), secciones 4.3 y 4.5 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), sección 4.3 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5